Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.

G, DʼHaens; W, Reinisch; R, Panaccione; J, Satsangi; J, Petersson; M, Bereswill; D, Arikan; E, Perotti; AM, Robinson; J, Kalabic; G, Alperovich; R, Thakkar; EV, Loftus

doi:10.1038/s41395-018-0098-4

Public

Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.

Shared by NobleBlocks on Jun 5, 2018 • 12:00 AM UTC

Authors:

DʼHaens G

Reinisch W

Panaccione R

Abstract

<h4>Objectives</h4>Real-world, prospective, long-term studies in Crohn's disease (CD) characterizing adalimumab safety data and lymphoma risk were lacking. We present the final results from the PYRAMID registry, which was designed to rule out a doubling of lymphoma risk in adalimumab-treated patient...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!